Table 1: Ongoing Clinical trials in MCC.
| NCT Identifier | Title | Phase | Treatment |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon beta and Avelumab with or without Cellular Adoptive Immunotherapy in Treating Patients with Metastatic Merkel Cell Carcinoma | 1/2 | Aveluma, Merkel cell polyomavirus TAg- specific polyclonal autologous CD8-positive T cells, Interferon beta, RT |
| NCT02643303 | A Phase 1/2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab plus Poly ICLC in Subjects with Advanced, Measurable, Biopsy-Accessible Cancers | 1/2 | Durvalumab, Tremelimumab, Poly ICLC |
| NCT 02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-Associated Tumors (CheckMate 358) | 1/2 | Nivolumab, Ipilimumab, BMS-986016, Daratumumab |
| NCT 03071406 | Randomized Study of Nivolumab plus Ipilimumab +/- SBRT for Metastatic Merkel Cell Carcinoma | 2 | Nivolumab, Ipilimumab, SBRT |
| NCT02196961 | Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma with Immune Checkpoint Blocking Antibodies versus Observation (ADMEC-O) | 2 | Ipilimumab, Nivolumab |
| NCT03271372 | Adjuvant Avelumab in Merkel Cell Cancer (ADAM) | 3 | Avelumab |